

LISTING OF CLAIMS

1. (Original) A dosage form comprising a prostaglandin or a prostamide and a trefoil factor family peptide.
2. (Original) The dosage form of claim 1 wherein the concentration of the prostaglandin or prostamide is from 0.001% to 0.1%.
3. (Original) The dosage form of claim 1 wherein the concentration of the trefoil factor family peptide is from 0.001% to 1%.
4. (Original) The dosage form of claim 1 wherein the concentration of the trefoil factor family peptide is from 0.01% to 0.5%.
5. (Original) The dosage form of claim 1 wherein the concentration of the trefoil factor family peptide is from 0.1% to 0.2%.
6. (Original) The dosage form of claim 1 wherein the concentration of the trefoil factor family peptide is about 0.15%.
7. (Original) The dosage form of claim 1 which further comprises a mucoadhesive.
8. (Original) The dosage form of claim 1 which further comprises a polysaccharide.
9. (Original) The dosage form of claim 1 which further comprises Tamarind seed polysaccharide.
10. (Original) The dosage form of claim 1 wherein the trefoil family factor peptide is TFF3.
11. (Original) The dosage form of claim 1 wherein the trefoil family factor peptide is TFF1.
12. (Original) The dosage form of claim 1 wherein said dosage form comprises bimatoprost.
13. (Original) The dosage form of claim 9 which comprises bimatoprost.
14. (Withdrawn) A method of treating ocular or conjunctival hyperemia in a person comprising administering topically to an eye of said person a therapeutically effective amount of a trefoil factor family peptide, wherein said person is being treated for glaucoma or elevated intraocular pressure with a prostaglandin-related compound.
15. (Withdrawn) The method of claim 14 wherein the trefoil factor family peptide and the prostaglandin-related compound are administered in a single composition.
16. (Withdrawn) The method of claim 14 wherein the trefoil factor family peptide and the prostaglandin-related compound are administered separately.
17. (Withdrawn) The method of claim 14 wherein said trefoil factor family peptide is administered in a dosage form comprising a mucoadhesive.
18. (Withdrawn) The method of claim 14 wherein said trefoil factor family peptide comprises TFF1 or TFF3.
19. (Withdrawn) The method of claim 17 wherein said person is being treated with bimatoprost.
20. (Withdrawn) The method of claim 17 wherein said mucoadhesive comprises a polysaccharide.
21. (Withdrawn) The method of claim 19 wherein said trefoil factor family peptide is administered with Tamarind seed polysaccharide.

22. (Original) The dosage form of claim 1, wherein said prostaglandin or prostamide is a prostaglandin F-related compound.
23. (Original) The dosage form of claim 2 which comprises Tamarind seed polysaccharide, about 0.5% sodium chloride, about 0.005% benzalkonium chloride, and about 0.6% of a borate buffer wherein the pH of the composition is adjusted to from about 6 to about 8.
24. (Original) The dosage form of claim 23 which comprises about 0.03% bimatoprost.
25. (Original) The dosage form of claim 23 which comprises about 0.005% latanoprost.
26. (Original) The dosage form of claim 23 which comprises about 0.004% travoprost.
27. (Original) The dosage form of claim 23 which comprises about 0.15% unoprostone isopropyl.
28. (Original) A pharmaceutical product comprising a composition comprising a therapeutically effective amount of a prostaglandin F-related compound and a therapeutically effective concentration of a trefoil factor family peptide, and a package suitable for ophthalmic use from which said composition is dispensed, wherein the use of the composition for the prevention or treatment of glaucoma is indicated thereon.